Similar Search Results

The cost of contract renegotiation: Evidence from the local public sector

Gagnepain, Philippe; Ivaldi, Marc; Martimort, David - C.E.P.R. Discussion Papers - 2010

The renegotiation of regulatory contracts is known to prevent regulators from achieving the full commitment efficient outcome in dynamic contexts. However, assessing the cost of such renegotiation remains an open issue from an empirical viewpoint. To address this question, we fit a structural...

Persistent link: https://www.econbiz.de/10008684689

Debt Contracts, Collapse and Regulation as Competition Phenomena

Gersbach, Hans; Uhlig, Harald - C.E.P.R. Discussion Papers - 1997

lenders, which may make lending altogether unprofitable. Second, banks can have an incentive to offer a debt contract and … additional equity contracts to intermediate debtors, which is in turn dominated by a simple debt contract, only attractive for … seek to avoid the contract with the highest chance of delivery: that contract attracts all bad entrepreneurs. …

Persistent link: https://www.econbiz.de/10005661861

Competition in the Pharmaceutical Industry: How do Quality Differences Shape Advertising Strategies?

de Frutos, Maria-Angeles; Ornaghi, Carmine; Siotis, Georges - C.E.P.R. Discussion Papers - 2010

We present a Hotelling model of price and advertising competition between prescription drugs that differ in quality/side e¤ects. Advertising results in the endogenous formation of two consumer groups: brand loyal and non-brand loyal ones. We show that advertising strategies are strategic...

Persistent link: https://www.econbiz.de/10008680762

Does Europe have an innovation policy? The case of EU economic law

Battaglia, Lauren; Larouche, Pierre; Negrinotti, Matteo - C.E.P.R. Discussion Papers - 2011

pharmaceuticals, specifically drug reformulation regulatory gaming. …

Persistent link: https://www.econbiz.de/10009205060

Investments in Pharmaceuticals Before and After TRIPS

Kyle, Margaret K; McGahan, Anita M - C.E.P.R. Discussion Papers - 2011

This paper addresses the relationship between patent protection and investment in the development of new pharmaceutical treatments. The TRIPS Agreement, which specifies minimum levels of intellectual property protection for countries in the World Trade Organization, has increased levels of...

Persistent link: https://www.econbiz.de/10009002387

Market Size and Pharmaceutical Innovation

de Mouzon, Oliver; Dubois, Pierre; Scott Morton, Fiona; … - C.E.P.R. Discussion Papers - 2011

the hypothesis that innovation in pharmaceuticals is becoming more difficult and expensive over time, as costs of …

Persistent link: https://www.econbiz.de/10009003149

Pharmaceuticals - Who's Afraid of `1992'?

Klepper, Gernot - C.E.P.R. Discussion Papers - 1992

creating an internal market for pharmaceuticals can be analysed. In a model of third-degree price discrimination, arbitrage … Market in pharmaceuticals are ambiguous, since a movement from segmented and price-controlled markets towards integrated …

Persistent link: https://www.econbiz.de/10005114350

Vaccines vs. Preventives

Kremer, Michael; Snyder, Christopher - C.E.P.R. Discussion Papers - 2015

Preventives are sold ex ante, before disease status is realized, while treatments are sold ex post. Even if the mean of the ex ante distribution of consumer values is the same as that ex post, the shape of the distributions may differ, generating a difference between the surplus each product can...

Persistent link: https://www.econbiz.de/10011196028

Identifying Industry Margins with Unobserved Price Constraints: Structural Estimation on Pharmaceuticals

Dubois, Pierre; Lasio, Laura - C.E.P.R. Discussion Papers - 2014

We provide a method allowing to identify margins in an oligopoly price competition game when prices may not be freely chosen in some markets, for example due to regulation. We use our identification strategy to study the effects of regulatory constraints in the pharmaceutical industry, which is...

Persistent link: https://www.econbiz.de/10011083879

Parallel Imports and Price Controls

Grossman, Gene; Lai, Edwin - C.E.P.R. Discussion Papers - 2006

pharmaceuticals. We challenge this orthodox view and show, to the contrary, that the pace of innovation often is faster in a world …

Persistent link: https://www.econbiz.de/10005666872